Cargando…
Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo
Prolyl oligopeptidase (PREP) inhibition by small-molecule inhibitors can reduce alpha-synuclein (aSyn) aggregation, a key player in Parkinson’s disease pathology. However, the significance of PREP protein for aSyn aggregation and toxicity is not known. We studied this in vivo by using PREP knock-out...
Autores principales: | Svarcbahs, Reinis, Julku, Ulrika H., Norrbacka, Susanna, Myöhänen, Timo T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784134/ https://www.ncbi.nlm.nih.gov/pubmed/29367610 http://dx.doi.org/10.1038/s41598-018-19823-y |
Ejemplares similares
-
Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner
por: Julku, Ulrika H., et al.
Publicado: (2021) -
Nonpeptidic
Oxazole-Based Prolyl Oligopeptidase Ligands
with Disease-Modifying Effects on α-Synuclein Mouse Models
of Parkinson’s Disease
por: Kilpeläinen, Tommi P., et al.
Publicado: (2023) -
Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease
por: Kilpeläinen, Tommi, et al.
Publicado: (2019) -
Prolyl oligopeptidase inhibition reduces alpha‐synuclein aggregation in a cellular model of multiple system atrophy
por: Cui, Hengjing, et al.
Publicado: (2021) -
Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington’s disease
por: Norrbacka, Susanna, et al.
Publicado: (2019)